The Power of Medicines: Saving lives and building for the future

By Holly Campbell

News provided by

Pharmaceutical Research and Manufacturers of America (PhRMA)

20 Oct, 2015, 02:36 ET

WASHINGTON, Oct. 20, 2015 /PRNewswire-USNewswire/ -- Over the last 25 years, medicines have helped change the way patients are treated and helped those diagnosed with debilitating diseases live longer, healthier lives.

View our new video here: https://www.youtube.com/watch?v=R3B9lgK2GXs

Not long ago HIV was an acute, fatal illness.

Today, thanks in part to innovative medicines, the U.S. death rate for HIV/AIDS has fallen nearly 85 percent since its peak, and is now considered by many to be a manageable chronic disease.

Therapeutic advances have also transformed treatment of rheumatoid arthritis. Previous treatments were limited to addressing the symptoms of the disease. Now, medicines target the underlying sources of inflammation, halting progression of the disease.

Today's medicines are at the forefront of science with many new treatments taking a targeted approach to attacking underlying causes of disease. Nearly 70 percent of medicines in the pipeline are potential first-in-class therapies, meaning they use a completely new approach to fighting a disease. These advances are opening doors for the development of the first new treatments for many rare diseases and other unmet medical needs.

Medicines can continue to save lives and be part of the solution to reducing medical spending, but only if we have a health care system that supports innovation and encourages the development of new treatments for Alzheimer's disease and other costly conditions.

Watch our new video and visit www.phrma.og/cost to learn more about the value medicines provide to patients and their families.

Learn more at www.phrma.org/cost

This post originally appeared here: http://catalyst.phrma.org/new-video-saving-lives-and-building-for-the-future

Contact: Holly Campbell; 202-835-3460; [email protected]

Video - https://www.youtube.com/watch?v=R3B9lgK2GXs

Logo - http://photos.prnewswire.com/prnh/20091027/PHRMALOGO

SOURCE Pharmaceutical Research and Manufacturers of America (PhRMA)

Also from this source

New report shows high-impact R&D happens after cancer medicines are first approved

New Analysis: Inflation Reduction Act Undermines Cancer Medicine Development

Explore

More news releases in similar topics

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.